Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

David B. Page, Harry Bear, Sangeetha Prabhakaran, Margaret E. Gatti-Mays, Alexandra Thomas, Erin Cobain, Heather McArthur, Justin M. Balko, Sofia R. Gameiro, Rita Nanda, James L. Gulley, Kevin Kalinsky, Julia White, Jennifer Litton, Steven J. Chmura, Mei Yin Polley, Benjamin Vincent, David W. Cescon, Mary L. Disis, Joseph A. SparanoElizabeth A. Mittendorf, Sylvia Adams

Research output: Contribution to journalReview article

1 Scopus citations


Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

Original languageEnglish (US)
Article number34
Journalnpj Breast Cancer
Issue number1
StatePublished - Dec 1 2019


ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Page, D. B., Bear, H., Prabhakaran, S., Gatti-Mays, M. E., Thomas, A., Cobain, E., McArthur, H., Balko, J. M., Gameiro, S. R., Nanda, R., Gulley, J. L., Kalinsky, K., White, J., Litton, J., Chmura, S. J., Polley, M. Y., Vincent, B., Cescon, D. W., Disis, M. L., ... Adams, S. (2019). Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. npj Breast Cancer, 5(1), [34].